Assessment of Adherence to Creatine-Based Nutritional Supplementation in Estrogen-Depleted Adult Women: Prospective Clinical Investigation

What this Trial Is About

Researchers are conducting a prospective, multicenter observational study to understand how well estrogen-depleted adult women, including those in menopause or late perimenopause, adhere to a creatine-based nutritional supplement called Creaticare FEM. The study aims to describe the percentage of doses consumed and the proportion of women achieving high adherence (80% or more) over 12 weeks. It also looks at persistence, satisfaction, tolerability, and adherence to physical activity recommendations, along with exploratory measures like muscle strength, body composition, quality of life, joint pain, and skin health. Participants will take a daily 10-gram dose of Creaticare FEM, which contains creatine monohydrate, hydrolyzed collagen, hyaluronic acid, beta-alanine, magnesium, and vitamins A, C, E, and B6, for 12 weeks. Alongside supplementation, they receive general physical activity advice consistent with usual clinical care, without supervised exercise or randomization. The study is observational and does not include control groups or experimental interventions beyond routine supplementation. During the 12-week period, women will attend planned visits and complete various assessments, including self-reported adherence to the supplement and physical activity, adverse event monitoring, and questionnaires on satisfaction. Exploratory assessments will measure changes in muscle strength, body composition, quality of life, joint pain, and skin health. The study seeks to provide real-world information on how well this nutritional supplement is accepted and tolerated in this population.

ATENEA Study: Adherence to Creatine-Based Nutritional Supplementation in Estrogen-Depleted Women